Sarbajit Mukherjee

Clinical Assistant Professor, Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York (SUNY), Buffalo, NY

Dr. Sarbajit Mukherjee is a gastrointestinal medical oncologist with a clinical and research focus on gastroesophageal cancer. Dr. Mukherjee obtained his medical degree in India in 2010. He then moved to the US and subsequently completed a residency in Internal Medicine in 2012. He started his fellowship training in Hematology-Oncology at the University of Oklahoma in 2015. He gained additional experience in translational research and clinical trial design through a Master’s program in clinical and translational science. Dr. Mukherjee’s work has resulted in several national/international presentations and peer-reviewed publications.

Dr. Mukherjee has been on several national committees. He served as a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee and the Professional Development Committee at the American Society of Clinical Oncology (ASCO). He currently serves as a panel member at National Comprehensive Cancer Network (NCCN). He is also a member of the board of directors at Esophageal Cancer Action Network (ECAN). Dr. Mukherjee has peer-reviewed for multiple scientific journals.

Dr. Mukherjee has received several awards including memberships in Alpha Omega Alpha medical honor society and Gold Humanism Honor Society. He also received a merit award from ASCO for his research on cancer immunotherapy.

Dr. Mukherjee’s current work involves understanding the biology of gastroesophageal cancer (GEC) as well as designing novel clinical trials to improve patient outcomes. His team is currently developing a cohort of new patient-derived xenograft (PDX), organoid and spheroid models of esophageal adenocarcinoma. Dr. Mukherjee is also interested in studying mechanisms of immune dysfunction in obese cancer patients and the use of immune checkpoint inhibitors in solid tumors, especially GEC.

Articles Published in Annals of Translational Medicine

Pembrolizumab in advanced gastric cancer: pioneering or prosaic?